// App-Quantinova.ai

2648 : Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.

Researchers

Presenter

  • Timothy McKeithan

Principal Investigators

  • Jude Fitzgibbon

  • Kai Fu

  • Dennis D Weisenburger

  • Timothy C. Greiner

  • Randy D. Gascoyne

  • Andreas Rosenwald

  • Elias Campo

  • Lisa M. Rimsza

  • Jan Delabie

  • Elaine S. Jaffe

  • Cynthia Lachel

  • Louis M. Staudt

  • Wing-Chung Chan

  • George W. Wright

  • Javeed Iqbal

  • Lynette M. Smith

  • Zhongfeng Liu

  • Can Kucuk

  • Francesco Bertoni

  • Andrea Rinaldi

Medical Centers

  • Pharmacology, University of Arizona, Tucson, AZ

  • University of Nebraska Medical Center, Omaha, NE

  • Hematologia, Hospital Clinic, Barcelona, Spain

  • Department of Medical Oncology, BC Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

  • Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland IOSI, Bellinzona, Switzerland

  • Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

  • Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany

Locations

  • Canada

  • Norway

  • Spain

  • Germany

  • Switzerland

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Follicular lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Lymphomas

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 6

  • beta-2 microglobulin

  • Phosphatase and tensin homolog

  • cMYC

  • Cyclin Dependent Kinase Inhibitor 2A

  • Major Histocompatibility Complex, Class I, A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved